Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded tirzepatide in appetite suppression Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the a ...

Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved kidney function. 37.5% had increased urinary VEGF levels, suggesting better blood vessel support in the kidneys. 36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. CRANBURY, N.J., A ...

CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly statistically significant. The Company reported positive topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucago ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment (p<0.005). Symptomatic Remission: Achieved in 56% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment. Safety and Tolerability: Excellent, with no adverse events. Licensing: Discussions advancing with multiple big pharma ...

Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted "orphan drug" designation to PL7737, an oral treatment that activates the melanocortin-4 rece ...

Palatin Technologies, Inc. (NYSE:PTN) Q2 2025 Earnings Conference Call February 13, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary Conference Call Participants Joe Pantginis - H. C. Wainwright Operator Greetings. Welcome to Palatin Technologies, Inc.'s Second Quarter Fiscal Year 2025 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (Sta ...

Core Insights - Palatin Technologies, Inc. announced financial results for its fiscal second quarter ended December 31, 2024, and completed database lock for its Phase 2 obesity co-administration study involving MC4R agonist bremelanotide and GLP-1/GIP dual agonist tirzepatide [1][5]. Financial Results - The company did not record any product sales for the second quarter ended December 31, 2024, following the sale of Vyleesi's worldwide rights for up to $171 million in December 2023. In the same quarter of 2023, gross product sales were $4.3 million, with net product revenue of $2.0 million [7]. - Total operating expenses for the quarter were $2.6 million, net of a $2.5 million gain on the sale of Vyleesi, compared to $0.9 million in the same quarter of the previous year, which included a $7.8 million gain on the sale of Vyleesi [8]. - The net loss for the quarter was $2.4 million, or $(0.12) per share, a decrease from a net loss of $7.8 million, or $(0.56) per share, in the same period of 2023 [11][12]. - As of December 31, 2024, cash and cash equivalents were $3.4 million, an increase from $2.4 million at September 30, 2024, but down from $9.5 million as of June 30, 2024 [13]. Obesity Programs - The completion of database lock for the Phase 2 obesity study is seen as a significant advancement in providing alternative treatments for obesity, with topline results expected later this month [2][5]. - The company is developing next-generation selective MC4R long-acting peptides and oral small molecules, targeting general obesity, weight loss management, and rare conditions like hypothalamic obesity [6]. - Investigational new drug (IND) enabling activities are expected to commence in the first quarter of 2025, with IND filings anticipated in the second half of 2025 [6]. Other Programs - The company is also advancing programs for dry eye disease, ulcerative colitis, and diabetic nephropathy, with topline data readouts expected for the ulcerative colitis treatment later this quarter [4][14].

CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. ...

CRANBURY, N.J., Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a regist ...